Results of the British Gynaecological Cancer Society survey
| Question 1 Answer | Which staging system is used in the reports of gynaecological cancer specimens in your unit? | |||
| FIGO 20 | TNM 0 | FIGO and TNM 2 | None 0 | |
| Question 2 Answer | In your gynaecological MDT meeting, which staging system is used? | |||
| FIGO 23 | TNM 0 | FIGO and TNM 0 | None 0 | |
| Question 3 Answer | Which staging system do you consider should be used for gynaecological cancers? | |||
| FIGO 18 | TNM 0 | FIGO and TNM 5 | None 0 | |
| Question 4 Answer | Does your MDT group have a preference as to which staging system should be used for gynaecological cancers? | |||
| FIGO 22 | TNM 0 | FIGO and TNM 1 | None 0 | |
| Question 5 Answer | Would you support the use of TNM as well as FIGO staging for selected gynaecological cancers? For example, it has been suggested that TNM is useful for cervical cancers (FIGO does not take into account the lymph-node status in the staging of these neoplasms). | |||
| Yes 19 No 4 | ||||
| Question 6 | Would you support the use of TNM instead of FIGO staging for selected gynaecological cancers bearing in mind the comment in question 5 about TNM being useful for cervical cancers to take into account the lymph-node status? | |||
| Answer | Yes 2 No 21 | |||
Results are numbers out of 23 respondents.
FIGO, Fédération Internationale de Gynécologie et d'Obstétrique.